Nuvalent, Inc.
The research record contains a warning or limitation that requires review before a complete Wall Street Score can be published. Available company and financial research remain accessible.
NUVL · Price history
Company & revenue
About Nuvalent, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain.
How they make money
Nuvalent is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future milestone payments or royalties from collaborative agreements to fund the research and development of its pipeline of targeted kinase inhibitors for cancer treatment.
Products & services
The company is developing a pipeline of small-molecule kinase inhibitors, including zidesamtinib (NVL-520) for ROS1-positive NSCLC, neladalkib (NVL-655) for ALK-positive NSCLC, and NVL-330 for HER2-mutant NSCLC.
Brands & revenue mix
Lead clinical-stage candidate for ROS1-positive NSCLC.
Separate brand revenue is not available in this research.Source
Clinical-stage candidate for ALK-positive NSCLC.
Separate brand revenue is not available in this research.Source
Clinical-stage candidate for HER2-mutant NSCLC.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of drug substances and drug products for clinical trials.Source
Competitors
- Pharmaceutical and biotechnology companies — Companies developing targeted therapies for oncology, specifically those targeting ROS1, ALK, and HER2 mutations in non-small cell lung cancer.Source
Strengths
Sources
Company-specific research
Questions worth answering for NUVL
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can NUVL fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is NUVL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for NUVL to reach sustainable profitability?
- •What future growth or profitability would be needed to justify NUVL's current valuation?
- •What does the current missing revenue history warning mean for the reliability or interpretation of NUVL's score?
Essential Investment Snapshot
Market Cap
$9.13B
P/E Ratio
-20.5
EPS
$-6.06
52-Week High
$123.99
52-Week Low
$71.13
Beta
1.14
Analyst Target
$124.00
Shares Outstanding
72.7M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$16.16
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Community Sentiment
0 active · 0 total callsNo personal call yet on NUVL.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary kinase-focused drug design platform.
- +Experienced management team in oncology drug development.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on third-party manufacturers and clinical trial sites.
- −Uncertainty of clinical trial success and regulatory approval.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$123.96
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Research & Development | $316.2M | $307.0M | $217.8M | $113.2M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $122.7M | $107.3M | $62.6M | $36.2M | ···· | ···· | ···· | ···· |
| Operating Expenses | $438.9M | $414.3M | $280.4M | $149.5M | ···· | ···· | ···· | ···· |
| EBITDA | -$334.4M | -$10.5M | $20.4M | -$126.2M | ···· | ···· | ···· | ···· |
| Operating Income | -$438.9M | -$414.3M | -$280.4M | -$149.5M | ···· | ···· | ···· | ···· |
| Interest Expense | $12.9M | $0.00 | $0.00 | $23.3M | ···· | ···· | ···· | ···· |
| Income Before Tax | -$449.5M | -$424.8M | -$260.0M | -$126.2M | ···· | ···· | ···· | ···· |
| Income Tax Expense | $596K | $585K | $764K | $0.00 | ···· | ···· | ···· | ···· |
| Net Income | -$450.1M | -$425.4M | -$260.8M | -$126.2M | ···· | ···· | ···· | ···· |
| Basic EPS | $-6.06 | $-5.85 | $-3.93 | $-2.17 | ···· | ···· | ···· | ···· |
| Basic Shares | 78.67M | 72.69M | 66.41M | 58.22M | ···· | ···· | ···· | ···· |
| Diluted Shares | 78.67M | 72.69M | 66.41M | 58.22M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.39
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
+32.2%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
Potential Score Impact
Positive indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 17.8%. Cash increased 32.2%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyRumor Mill · NUVL
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial